Company intelligence / Profile preview
MIMEDX
- Ownership
- Public · MDXG
- Employees
- ~700
- Development stage
- Commercial
Overview
MIMEDX has demonstrated clinical efficacy in multiple randomized controlled trials for its placental tissue allograft products. Its lead product EPIFIX is widely used in the treatment of chronic wounds such as diabetic foot ulcers with strong payer coverage. The company continues to expand indications through additional clinical studies[3].
- Therapeutic areas
- OtherDermatology
- Modalities
- Placental tissue allografts (including dehydrated human amnion/chorion membrane, dehydrated human umbilical cord, lyophilized placental-based membranes)
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $478.6M
- Total revenue
- $418.6M
- Enterprise value
- $357.8M
Beyond the preview
Go deeper on MIMEDX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIMEDX.